AG真人官方

Arteris, Inc. (AIP) 鈥� Form 4 insider transaction filing

Vice President & Chief Financial Officer Nicholas B. Hawkins reported four open-market sales totalling 8,837 common shares during July 2025 at a weighted-average price of approximately $9.09 per share.

• 07/02/2025: Three sales (1,489 sh, 891 sh, 1,509 sh) at $8.9924 each, executed solely to satisfy tax-withholding obligations stemming from the release of restricted stock units (RSUs).
• 07/07/2025: Sale of 4,948 sh at a weighted average price of $9.2207; transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20-May-2024.

After these transactions, Hawkins鈥� direct beneficial ownership stands at 130,548 shares, down from roughly 139,385 shares, a reduction of about 6.3 % of his prior holdings. No derivative security activity was reported.

The filing does not disclose any option exercises, purchases, or new awards. All sales were made on the open market; the price range for the 07/07 trades was $9.00鈥�$9.35.

Because a portion of the shares sold covered RSU-related tax liabilities and the remainder was executed under a previously established 10b5-1 plan, the transactions appear routine rather than opportunistic. Nevertheless, investors may note the modest decrease in insider ownership by a key executive.

Arteris, Inc. (AIP) 鈥� Form 4 insider transaction filing

Vice President & Chief Financial Officer Nicholas B. Hawkins reported four open-market sales totalling 8,837 common shares during July 2025 at a weighted-average price of approximately $9.09 per share.

• 07/02/2025: Three sales (1,489 sh, 891 sh, 1,509 sh) at $8.9924 each, executed solely to satisfy tax-withholding obligations stemming from the release of restricted stock units (RSUs).
• 07/07/2025: Sale of 4,948 sh at a weighted average price of $9.2207; transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20-May-2024.

After these transactions, Hawkins鈥� direct beneficial ownership stands at 130,548 shares, down from roughly 139,385 shares, a reduction of about 6.3 % of his prior holdings. No derivative security activity was reported.

The filing does not disclose any option exercises, purchases, or new awards. All sales were made on the open market; the price range for the 07/07 trades was $9.00鈥�$9.35.

Because a portion of the shares sold covered RSU-related tax liabilities and the remainder was executed under a previously established 10b5-1 plan, the transactions appear routine rather than opportunistic. Nevertheless, investors may note the modest decrease in insider ownership by a key executive.

Tectonic Therapeutic, Inc. (Nasdaq: TECX) has filed a Form S-3 shelf registration that allows the company to issue up to $400 million of common stock, preferred stock, debt securities and/or warrants. The filing also includes a dedicated $100 million at-the-market (ATM) sales agreement with TD Securities (USA) LLC, giving management flexibility to raise capital "from time to time" as clinical milestones approach.

The prospectus reiterates Tectonic鈥檚 strategy of developing biologics that modulate GPCRs via its proprietary GEODe鈩� platform. Lead asset TX45 (Fc-relaxin fusion) has completed a Phase 1a study showing good tolerability and a favourable PK/PD profile. In Part A of an ongoing Phase 1b hemodynamic trial in PH-HFpEF patients, TX45 achieved a 19% reduction in pulmonary capillary wedge pressure and a >30% PVR reduction in a severe sub-population, with no serious adverse events. Recruitment is under way for Part B (PH-HFrEF), and the 24-week placebo-controlled Phase 2 APEX trial dosed its first patient in October 2024; topline data are expected in 2026.

Second program TX2100, a VHH-Fc fusion for Hereditary Hemorrhagic Telangiectasia, entered IND-enabling studies in Q2 2025, with a Phase 1 start targeted for late 2025/early 2026. The company completed a reverse-merger with Legacy Tectonic in June 2024 and now qualifies as a smaller reporting company. Proceeds from any sales under the shelf will fund pipeline advancement, working capital and potential in-licensing.

As of 3 July 2025 the stock traded at $21.34 per share. While the registration itself is not a financing event, it signals possible future dilution balanced by improved funding optionality ahead of multiple clinical catalysts.

Arteris, Inc. (NASDAQ: AIP) 鈥� Form 144 filing discloses that a shareholder intends to sell up to 1,554 common shares through Morgan Stanley Smith Barney on or after 07 / 03 / 2025. The estimated aggregate market value is $14,125.86. Total shares outstanding are 41,977,728, so the proposed sale represents roughly 0.0037 % of shares outstanding.

The filer鈥攊dentified in the accompanying sales history as 鈥�10b5-1 Sales Plan for Laurent Moll鈥� and 鈥�Laurent Moll鈥濃�攈as already disposed of 2,368 shares over the past three months through multiple Rule 10b5-1 transactions, generating $16,743 in gross proceeds. Combined with the new notice, total contemplated and recent sales amount to 3,922 shares, or approximately 0.009 % of outstanding shares.

No information on the seller鈥檚 relationship to Arteris, the purpose of the sale, or any material, non-public information is provided, and the standard Rule 144 representation affirms the seller鈥檚 lack of undisclosed adverse knowledge. Given the de-minimis size relative to the public float, the filing is unlikely to have a material impact on AIP鈥檚 share price, but investors may note the continued insider selling trend.

Arteris, Inc. (NASDAQ: AIP) 鈥� Form 144 filing discloses that a shareholder intends to sell up to 1,554 common shares through Morgan Stanley Smith Barney on or after 07 / 03 / 2025. The estimated aggregate market value is $14,125.86. Total shares outstanding are 41,977,728, so the proposed sale represents roughly 0.0037 % of shares outstanding.

The filer鈥攊dentified in the accompanying sales history as 鈥�10b5-1 Sales Plan for Laurent Moll鈥� and 鈥�Laurent Moll鈥濃�攈as already disposed of 2,368 shares over the past three months through multiple Rule 10b5-1 transactions, generating $16,743 in gross proceeds. Combined with the new notice, total contemplated and recent sales amount to 3,922 shares, or approximately 0.009 % of outstanding shares.

No information on the seller鈥檚 relationship to Arteris, the purpose of the sale, or any material, non-public information is provided, and the standard Rule 144 representation affirms the seller鈥檚 lack of undisclosed adverse knowledge. Given the de-minimis size relative to the public float, the filing is unlikely to have a material impact on AIP鈥檚 share price, but investors may note the continued insider selling trend.

Barrett Business Services Inc. (BBSI) 鈥� Form 4 insider filing

Director Mark Steven Finn reported two equity transactions dated 1 July 2025:

• 593 common shares acquired at a conversion price of $0.00 following the vesting of an equal number of restricted stock units (RSUs). Post-transaction direct ownership rises to 14,443 shares.
• 2,344 new RSUs granted (transaction code 鈥淎鈥�) that vest in a single tranche on 1 July 2026. Finn now holds 2,344 RSUs outstanding.

No open-market purchases or sales occurred; the activity reflects normal equity incentive plan mechanics. The net change represents less than 0.1 % of BBSI鈥檚 ~7.0 million shares outstanding and therefore is not expected to be material for valuation.

Arteris, Inc. (AIP) Form 4 filing: Chief Operating Officer Laurent R. Moll sold 294 shares of common stock on 1 Jul 2025 through a pre-arranged Rule 10b5-1 trading plan adopted 12 Mar 2025. The weighted-average sale price was $9.0869 per share, with transactions executed between $8.81 and $9.32. After the sale, Moll directly owns 483,465 shares of Arteris common stock. No derivative security activity was reported.

The transaction represents less than 0.1 % of Moll鈥檚 reported holdings and does not appear material to the company鈥檚 capital structure.

Arteris, Inc. (AIP) 鈥� Form 4 Insider Transaction

Director S. Atiq Raza, acting through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, sold 19,809 shares of Arteris common stock on 27 June 2025 under a pre-arranged Rule 10b5-1 trading plan adopted on 6 June 2024. The weighted-average sale price was $10.02 per share (individual trade prices ranged from $10.00 to $10.10).

Following the transaction, the trust continues to hold 683,798 shares, leaving Mr. Raza with a substantial ownership position. The filing states that the trade was reported on 1 July 2025 and was executed indirectly through the trust.

• Form type: SEC Form 4
• Insider role: Director
• Nature of trade: Open-market sale (code 鈥淪鈥�)
• Approximate transaction value: $199,000

The relatively small percentage of shares sold (鈮�2.8 % of the insider鈥檚 reported holdings) and the existence of a 10b5-1 plan mitigate potential negative signalling, yet investors often monitor insider sales for sentiment clues.

Arteris, Inc. (AIP) 鈥� Form 4 insider transaction summary

The filing discloses two open-market sales of Arteris common stock by Nicholas B. Hawkins, the company鈥檚 Vice President & Chief Financial Officer. Both sales were executed under a Rule 10b5-1 trading plan adopted on 20 May 2024.

• 26 June 2025: 5,638 shares sold at $10.00 per share (transaction code 鈥淪鈥�), leaving 145,023 shares beneficially owned.
• 1 July 2025: 5,638 shares sold at a weighted-average price of $9.0806 (sales occurred between $8.72-$9.37), leaving 139,385 shares held directly.

Across both dates, Hawkins disposed of 11,276 shares鈥攁pproximately 7-8% of the 150,661 shares he held before these transactions. No derivative security activity was reported. The CFO remains a significant shareholder, which can help maintain alignment with investors.

This information is useful for tracking insider sentiment and potential supply-demand effects on AIP鈥檚 share price. Because the trades were pre-planned, the negative signaling effect of insider selling may be moderated.